Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-18
2010-06-22
Powers, Fiona T (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S419000, C514S420000, C514S441000, C514S514000, C548S467000, C548S500000, C549S037000, C558S017000
Reexamination Certificate
active
07741359
ABSTRACT:
The present invention relates to derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) having improved anti-inflammatory properties useful in the treatment of inflammation, pain and fever. More particularly, NSAIDs are derivatized with a hydrogen sulfide (H2S) releasing moiety to produce novel anti-inflammatory compounds having reduced side effects.
REFERENCES:
patent: 4412992 (1983-11-01), Chan et al.
patent: 4440763 (1984-04-01), Lover
patent: 5013727 (1991-05-01), Halskov
patent: 5811425 (1998-09-01), Woods et al.
patent: 6197341 (2001-03-01), Freiss et al.
patent: 6297260 (2001-10-01), Bandarage
patent: 6458776 (2002-10-01), Ekwuribe et al.
patent: 6602915 (2003-08-01), Uhrich et al.
patent: 7498355 (2009-03-01), Wallace et al.
patent: 7666907 (2010-02-01), Wallace et al.
patent: 2005/0215487 (2005-09-01), Holick et al.
patent: 2008/0020997 (2008-01-01), Capomacchia et al.
patent: 2009/0036516 (2009-02-01), Scherrer et al.
patent: 2009/0281093 (2009-11-01), Sparatore et al.
patent: 2009/0306412 (2009-12-01), Wallace et al.
patent: 2204747 (1997-03-01), None
patent: WO2006/037623 (2006-04-01), None
patent: WO 2006/066894 (2006-06-01), None
patent: WO 2006/111791 (2006-10-01), None
patent: WO 2006/125293 (2006-11-01), None
patent: WO 2006/125295 (2006-11-01), None
patent: WO2006/134489 (2006-12-01), None
patent: WO2007/101606 (2007-09-01), None
Van Boi et al., Chemical Abstracts, 132:293322, 2000.
Wallace, J.L. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology. 1997; 112:1000-1016.
Grosser et al., Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006; 116: 4-15.
Wang, Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J 2002; 16: 1792-1798.
Fiorucci et al., Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology. 2005; 129: 1210-1224.
Wallace et al., Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 1998; 115: 101-109.
Wallace et al., Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol 1999; 126:1200-1204.
Zanardo et al., Hydrogen sulphide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 2006; 20: 2118-2120.
Stadler et al., Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers. Digestive Diseases and Sciences 1991; 36: 594-600.
Elliott et al., A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524-530.
Whelton, A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am. J. Med. 1999; 106 (5B): 13S-24S.
Ribeiro et al. (Chronic inhibition of nitric oxide synthesis: A new model or arterial hypertension. Hypertension 1992; 20: 298-303.
Ubuka, T. Assay methods and biological roles of labile sulfur in animal tissues. J Chromatogr B Analyt Technol Biomed Life Sci. 2002, 781: 227-249.
Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous K(ATP) channel opener. EMBO J. 2001; 20: 6008-6016.
Dzierzewicz, et al., Susceptibility of Desulfovibrio desulfuricans intestinal strains to sulfasalazine and its biotransformation products, Med. Sci. Monit., 2004, vol. 10, No. 6, BR185-190.
Edmond, et al., The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing bacteria and amino acid-fermenting bacteria, Inflammatory Bowel Diseases, 2003, vol. 9, No. 1, pp. 10-17.
Distrutti, et al., Evidence that Hydrogen Sulfide exerts Antinociceptive Effects in the Gastrointestinal Tract by Activating KATP Channels, J. Pharmacology & Exp. Ther., Web Release on Sep. 25, 2005, vol. 316, No. 1, pp. 325-335.
Sidhu, et al., L-Cystein and Sodium Hydrogensulfide Inhibit Spontaneous Contractibility in Isolated Pregnant Rat Uterine Strips in Vivo, Pharmacology & Toxicology, 2001, vol. 88, pp. 198-203.
Zhao, et al., The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener, EMBO Journal, 2001, vol. 20, No. 21, pp. 6008-6016.
Zhao, et al., H2S-induced vasorelaxation and underlying cellular and molecular mechanisms, A. J. Physiol. Heart Circ. Physiol., 2002, vol. 283: H474-480.
Teague, et al., “The Smooth Muscle Relaxant Effect of Hydrogen Sulfide In Vitro: Evidence for a Physiological Role to Control Intestinal Contractility”, Br. J. Pharmacol, vol. 137, pp. 139-145.
Abe, et al., “The possible role of hydrogen sulfide as an endogenous neuromodulator”, The Journal of Neuroscience, 1996, vol. 16, No. 3, pp. 1066-1071.
Carceller, et al., “Novel Azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity”, J. Med. Chem., 2001, vol. 44, No. 18, pp. 3001-3013.
Pellicciari, et al., Brush-Border-Enzyme-Mediated Intestine-Specific Drug Delivery. Amino acid Prodrugs of 5-Aminosalicylic acid, J. Med. Chem. 1993, vol. 36, pp. 4201-4207.
Li et al., “Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative”, Free radical Biology & Medicine, vol. 42, No. 5, Mar. 1, 2007, p. 706-719.
Kourounakis et al., “Reduction of gastrointestinal toxicity of NSAIDs via molecular modifications leading to antioxidant anti-inflammatory drugs”, Toxicology (2000) vol. 144, No. 1-3, p. 205-210.
Galankis et al., “Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity”, Bioorganic & Medicinal Chemistry Letters, vol. 14 (2004), p. 3639-3643.
Bhatia et al., “Treatment with H2S-releasing derivative of diclofenac reduces inflammation in carrageenan-induced hindpaw oedema”, Inflammation Research, Suppl.2, 7th World Congress on Inflammation, Aug. 20-24, 2005, Melbourne, Australia.
Szabo et al., “Protection against aspirin-induced hemorrhagic erosions and mucosal vascular injury by co-administration of sulfhydryl drugs”, Gastroenterology (1985), vol. 88, No. 5 Part 2, p. 1604.
Fiorucci et al., “The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver”, Gastroenterology, Jul. 2006, vol. 131, No. 1, p. 259-271.
Fiorucci et al., Enhanced activity of hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis, British Journal of Pharmacology (2007), 150, 996-1002.
Distrutti et al., “5-Amino-2hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol03yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity”, The Journal of Pharmacology and Experimental Therapeutics 2006, vol. 319 No. 1, 447-458.
Schicho et al., “Hydrogen Sulfide is a Novel Prosecretory Neuromodulator in the Guinea-Pig and Human Colon”, Gastroenterology 2006, 131:1542-1552.
Wallace et al., “Gastrointestinal Safety and Anti-Inflammatory Effects of a Hydrogen Sulfide-Releasing Diclofenac Derivative in the Rat”, Gastroenterology 2007, 132:261-271.
Isenberg et al., “Modulation of angiogenesis by dithiolethione-modified NDAIDs and valproic acid”, British Journal of Pharmacology (2007) 151, 142-151.
Ling et al., “Anti Inflammatory activity of S-diclofenac, a novel H2S -releasing diclofenac derivative”, Abstracts, The 15th World Congress of Pharmacology, Jul. 2-7, 2006, P260055, pp. 270.
Kartasasmita, Rahmana E. et al.: “NO-donors (VII (1)) : Synthesis and cyclooxygenase inhibitory properties of N- and S- nitrooxypivaloyl-cysteine derivatives of naproxen: A n
Caliendo Giuseppe
Cirino Giuseppe
Santagada Vincenzo
Wallace John
Antibe Therapeutics Inc.
Bennett Jones LLP
Powers Fiona T
LandOfFree
Hydrogen sulfide derivatives of non-steroidal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydrogen sulfide derivatives of non-steroidal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrogen sulfide derivatives of non-steroidal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155596